Teaming up to tackle drug development complexity


Vetter and Rentschler Biopharma are collaboratively developing a best-in-breed approach that reduces time-to-market.

Dr. Frank Mathias, CEO Rentschler Biopharma SE and Peter Soelkner, Managing Director Vetter Pharma

With global demand surging, biopharma companies are under significant pressure to accelerate new products to the clinic and market. At the same time, both the cost and complexity of drug development are increasing rapidly. 

To meet these challenges, Vetter and Rentschler have formed a strategic collaboration to align their manufacturing approaches, streamline supply chains, and ultimately reduce development time for new biopharma products. Together, we and Rentschler aim to simplify and speed the process of delivering new therapies, while also creating long-term value for both companies’ biopharma customers.

In a recent exclusive interview, Rentschler CEO Dr. Frank Mathias and our Managing Director Peter Soelkner commented on their strategic vision for this collaboration, and shared some interesting news about an ongoing pilot project. Read the interview here.